Use of colistin in adult patients: A cross-sectional study. (March 2020)

• Record Type: Journal Article
• Authors: Giacobbe, Daniele Roberto; Saffioti, Carolina; Losito, Angela Raffaella; Rinaldi, Matteo; Aurilio, Caterina; Bolla, Cesare; Boni, Silvia; Borgia, Guglielmo; Carannante, Novella; Cassola, Giovanni; Ceccarelli, Giancarlo; Corcione, Silvia; Dalla Gasperina, Daniela; De Rosa, Francesco Giuseppe; Dentone, Chiara; Di Bella, Stefano; Di Lauria, Nicoletta; Feasi, Marcello; Fiore, Marco; Fossati, Sara; Franceschini, Erica; Gori, Andrea; Granata, Guido; Grignolo, Sara; Grossi, Paolo Antonio; Guadagnino, Giuliana; Lagi, Filippo; Maraolo, Alberto Enrico; Marinò, Valeria; Mazzitelli, Maria; Mularoni, Alessandra; Oliva, Alessandra; Pace, Maria Caterina; Parisini, Andrea; Patti, Francesca; Petrosillo, Nicola; Pota, Vincenzo; Raffaelli, Francesca; Rossi, Marianna; Santoro, Antonella; Tascini, Carlo; Torti, Carlo; Trecarichi, Enrico Maria; Venditti, Mario; Viale, Pierluigi; Signori, Alessio; Bassetti, Matteo; Del Bono, Valerio; Giannella, Maddalena; Mikulska, Malgorzata; Tumbarello, Mario; Viscoli, Claudio;
• Is Part Of: Journal of global antimicrobial resistance. Volume 20(2020)
• Page Start: 43
• Page End: 49
• Publication Date: 2020-03
• Subjects: Colistin -- Colistimethate -- Acinetobacter -- Pseudomonas -- Klebsiella -- Antimicrobial resistance; Drug resistance -- Periodicals; Drug resistance -- Periodicals; Drug resistance; Periodicals; 616.9041
• DOI: 10.1016/j.jgar.2019.06.009
• Languages: English
• ISSNs: 2213-7165

Abstract

Highlights: In a country endemic for MDR Gram-negative bacteria, colistin was mostly administered in combination with other agents. A loading dose of 9 MU of colistimethate was administered in 79% of patients and adequate maintenance doses in 85%. Empirical therapy and targeted therapy of CRE infection were associated with colistin use in combination with other agents. Colistin was mostly used appropriately, but efforts might be necessary to further increase rates of adequate loading doses. Abstract: Objectives: The aim of this study was to assess colistin use in a country endemic for multidrug-resistant Gram-negative bacteria (MDR-GNB). Methods: Colistin prescription patterns were evaluated in 22 Italian centres. Factors associated with use of colistin in combination with other anti-MDR-GNB agents were also assessed. Results: A total of 221 adults receiving colistin were included in the study. Their median age was 64 years (interquartile range 52–73 years) and 134 (61%) were male. Colistin was mostly administered intravenously (203/221; 92%) and mainly for targeted therapy (168/221; 76%). The most frequent indications for colistin therapy were bloodstream infection and lower respiratory tract infection. Intravenous colistin was administered in combination with at least another anti-MDR-GNB agent in 80% of cases (163/203). A loading dose of 9 MU of colistimethate was administered in 79% of patients receiving i.v. colistin and adequate maintenance doses in 85%. In multivariable analysis, empirical therapy [odds ratio (OR) = 3.25, 95% confidence interval (CI) 1.24–8.53; P = 0.017] and targeted therapy for carbapenem-resistant Enterobacterales infection (OR = 4.76, 95% CI 1.69–13.43; P = 0.003) were associated with use of colistin in combination with other agents, whilst chronic renal failure (OR = 0.39, 95% CI 0.17–0.88; P = 0.024) was associated with use of colistin monotherapy. Conclusion: Colistin remains an important option for severe MDR-GNB infections when other treatments are not available. Despite inherent difficulties in optimising its use owing to peculiar pharmacokinetic/pharmacodynamic characteristics, colistin was mostly used appropriately in a country endemic for MDR-GNB.